Pfizer Pharmaccuticals Limited

Pfizer Announces Expansion of Research and Development Operations in China

November 25,2009

First Major Facility of Top Global Pharmaceutical Giant in Midwest China (Biolake)

Nov. 25, 2009, Wuhan, China --Pfizer (China) Research and Development Co., Ltd. and Wuhan National Bioindustry Base Construction and Management Office today signed a Memorandum of Understanding to establish a new Pfizer R&D center in Wuhan. This new center, located in Biolake (Wuhan National Bioindustry Base), represents an expansion of Pfizer's existing R&D facility in Shanghai and will serve as a state-of-the-art platform for global drug development and strategic biomedical alliances, supporting the company's commitment to achieving a healthier China and a healthier world.
Among those who attended this signing ceremony were Guo Shenglian, the Vice Governor of Hubei Province; Allan Gabor, Regional President of Pfizer North Asia; officials from Hubei Provincial Government and Wuhan Municipal Government; and high-level representatives from Pfizer Global R&D organization.

"Pfizer is committed to working closely with China's healthcare community to strengthen the biomedical infrastructure throughout China," said Allan Gabor, Regional President for North Asia. "We're therefore excited to be establishing for the first time a significant R&D presence in Central/Western region. With plans to be a state-of-the-art facility, the Wuhan center will be an integral part of Pfizer's global R&D operations while being closely aligned with the Chinese government’s strategy on biopharmaceutical industry development in the region."

"Pfizer is setting up this R&D center in Wuhan primarily because of the city’s solid research foundation and rich talent pool," continued Lingshi Tan, Vice President of Pfizer Global Research & Development, General Manager of Pfizer (China) Research & Development Co., Ltd. "The establishment of Pfizer R&D operations in Wuhan will allow us to further expand our efforts to work alongside Chinese partners to promote biomedical innovation and develop the relevant skills and talents in local communities in central China."

Pfizer's R&D operations in Wuhan will be initially engaged in supporting various global clinical drug development programs, including Phase I-IV clinical trials. Once the facility is built, Pfizer expects the number of employees to grow to 200 within 3 years. Pfizer R&D in Wuhan will also liaise with local research institutes and universities utilizing the rich resources of local talent and existing industry capabilities to develop research collaborations on drug innovation and development. In the mean time, Shanghai will remain the operations hub of Pfizer's R&D effort in China.

Mr. Chuantie Liu, Secretary General of the Administrative Committee of the Wuhan East Lake Hi-tech Development Zone remarked, "Pfizer will be the first premier pharmaceutical company to reside in Biolake. Pfizer R&D in Wuhan will serve as a catalyst for the biopharmaceutical industry's development in Wuhan and the surrounding Midwest region of China. East Lake Hi-tech Development Zone will follow the principles of 'mutual benefit, mutual complementarity and common development' to provide better service for Pfizer's move-in and create a bright future together. "

About Biolake:

Wuhan National Bioindustry Base (Biolake) supports biopharmaceutical industry development in Wuhan National East Lake High-tech Zone, which is one of the future core backbone industries in Biolake. Since received approval from the National Committee of Development and Reform in June 2007, infrastructure construction in Biolake has been started and developing quickly. Up to now, the total investment is about RMB 13 billion. Within next 3-5 years, the Biolake town will be established covering approximately 12 sq km in the east of Wuhan.

The construction of Biolake started officially in Nov. 2008. So far, the infrastructures of water, electricity, road and gas have been fully launched and moved forward rapidly with a total investment of RMB 3 billion. Some 250,000 square meters of building space have been finished in the Innovation Base which will be available in 2010. There are nearly 30 manufacturing companies under construction in the Industry Base with total investment of RMB 6.6 billion, including some famous companies such as Sinopharm and Grand Pharmaceuticals, etc.

The development of Biolake was driven by the construction of Wuhan National Bioindustry Base. From Jan. to Oct. of this year, the bioindustry revenue of Wuhan East Lake Hi-tech Development Zone has reached RMB 15.7 billion, 25% increase comparing with last year. And it's anticipated to exceed RMB 20 billion in 2009.

For more information, please visit http://www.biolake.gov.cn/.

About Pfizer:

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 160 years, Pfizer has worked to make a difference for all who rely on us.

In China, Pfizer's mission is to meet the diverse medical needs of the country's 1.3 billion population in an innovative, socially responsible and commercially viable manner. We offer a broad portfolio of innovative medicines, actively partnering with healthcare providers, academics, and authorities to serve Chinese patients and to support the rapid development of the country's healthcare system.

For more information, please visit http://www.Pfizer.com.cn.

About Pfizer China Research and Development Center
Pfizer China Research and Development Center (CRDC) was established on October 31, 2005. Up to now, there are 350 employees, providing support to Pfizer worldwide biopharmaceutical research and development programs.
CRDC is engaged in study design, data management, statistical analysis, and study report preparation of global phase I-IV clinical trials. It also has a division of global Safety and Risk Management and covers the functions of safety data processing, assessment and narrative writing. Recently CRDC established a worldwide regulatory operations team for submission preparation and quality assurance in Asia Pacific region. Besides the drug development related functions, there is a dedicated research team for implementing and coordinating Pfizer's research strategy for Asia. The Asia Research team develops partnerships and forges alliances with academic researchers, CRO and government research institutions throughout Asia, to leverage R&D capabilities.
CRDC works alongside Chinese partners to develop the skills and talents of local scientists, biostatisticians, medical professionals, pharmacists, and others with expertise in life sciences. In addition, CRDC collaborates with leading academic researchers and top institutes in China including Peking University, Tsinghua University, Fudan University, the Chinese Academy of Science Institute of Biophysics, and the Chinese Academy of Science Shanghai Institute of Biochemistry and Cell Biology. By working with these partners, Pfizer strives to create an environment that will nurture research and innovative drug development in China.